Research at Beijing Scitech-Mq Pharmaceuticals Ltd. has led to the identification of inhibitors of epidermal growth factor receptor (EGFR; HER1; erbB1) and its mutants which are reported to be useful for the treatment of cancer and autoimmune diseases.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented benzodiazepine derivatives acting as GABA(A) receptor subunit α2β2γ1 positive allosteric modulators and reported to be useful for the treatment of neurological disorders.

Lysyl oxidase homologue 2 (LOXL2) inhibitors have been reported in a Yuhan Corp. patent as potentially useful for the treatment of idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis (NASH), chronic kidney disease and cirrhosis.

Petra Pharma Corp. has patented phosphatidylinositol 3-kinase α (PI3Kα, PIK3CA) (H1047R mutant) allosteric inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum.

Caraway Therapeutics Inc. has divulged mucolipin (MCOLN; TRPML) activators reported to be useful for the treatment of metabolic diseases, aging, cancer, ciliopathy, neurodegeneration and muscle disorders.

Michigan State University has identified microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of Alzheimer’s disease.

Chiesi Farmaceutici SpA has synthesized pyridazinyl amino derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported for be useful for the treatment of idiopathic pulmonary fibrosis (IPF).

Palacky University has disclosed platinum complexes reported to be useful for the treatment of multiple myeloma.

Lead Discovery Center GmbH and Qli5 Therapeutics GmbH have described macrocyclic compounds acting as proteasome subunit β type-5 (PSMB5) inhibitors reported to be useful for the treatment of cancer, infections, inflammatory disorders, myasthenia gravis and transplant rejection.

Shijiazhuang Discovery Medicine Technology Co. Ltd. has divulged pranoprofen derivatives reported to be useful for the treatment of pain and eye disorders.